.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
SURPASS-2 directly compared once-weekly tirzepatide with semaglutide 1 mg in adults with type 2 diabetes inadequately controlled on metformin. Across the studied tirzepatide doses, reductions in HbA1c and body weight were greater than with semaglutide. Gastrointestinal adverse events were the most common treatment-related effects and were generally mild to moderate. The trial is highly relevant to current diabetes practice because dual GIP/GLP-1 receptor agonism has expanded the therapeutic conversation beyond glucose lowering alone. For clinicians, the key point is not that one drug is universally superior, but that treatment selection can increasingly be personalized according to glycemic burden, weight goals, cardiovascular and kidney risk, injection burden, cost and patient preference. The study also illustrates the importance of interpreting head-to-head comparisons in the context of the doses used and the population studied. In routine practice, careful dose escalation and counseling around gastrointestinal effects can improve persistence. SURPASS-2 therefore fits naturally into discussions about moving from “HbA1c control” toward broader metabolic risk reduction.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
SURPASS-2 directly compared once-weekly tirzepatide with semaglutide 1 mg in adults with type 2 diabetes inadequately controlled on metformin. Across the studied tirzepatide doses, reductions in HbA1c and body weight were greater than with semaglutide. Gastrointestinal adverse events were the most common treatment-related effects and were generally mild to moderate. The trial is highly relevant to current diabetes practice because dual GIP/GLP-1 receptor agonism has expanded the therapeutic conversation beyond glucose lowering alone. For clinicians, the key point is not that one drug is universally superior, but that treatment selection can increasingly be personalized according to glycemic burden, weight goals, cardiovascular and kidney risk, injection burden, cost and patient preference. The study also illustrates the importance of interpreting head-to-head comparisons in the context of the doses used and the population studied. In routine practice, careful dose escalation and counseling around gastrointestinal effects can improve persistence. SURPASS-2 therefore fits naturally into discussions about moving from “HbA1c control” toward broader metabolic risk reduction.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
